Eli Lilly and (NYSE:LLY) Sets New 1-Year High at $447.51

Eli Lilly and Company (NYSE:LLY – Get Rating)’s stock price hit a new 52-week high on Friday . The stock traded as high as $447.51 and last traded at $442.53, with a volume of 944266 shares traded. The stock had previously closed at $437.89.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LLY. Jefferies Financial Group boosted their price objective on Eli Lilly and from $290.00 to $310.00 and gave the stock a “hold” rating in a report on Monday, April 3rd. Truist Financial boosted their price objective on Eli Lilly and from $421.00 to $430.00 in a report on Friday, April 28th. Citigroup dropped their price objective on Eli Lilly and from $370.00 to $360.00 and set a “buy” rating for the company in a report on Friday, March 3rd. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and from $430.00 to $475.00 in a report on Thursday, May 4th. Finally, UBS Group upped their price target on Eli Lilly and from $438.00 to $447.00 in a research note on Friday, April 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $415.75.

Eli Lilly and Trading Up 1.0 %

The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.02 and a current ratio of 1.30. The business has a 50-day simple moving average of $378.15 and a two-hundred day simple moving average of $360.18. The stock has a market cap of $419.94 billion, a price-to-earnings ratio of 70.33, a P/E/G ratio of 2.33 and a beta of 0.37.

Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings results on Thursday, April 27th. The company reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.73 by ($0.11). The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.87 billion. Eli Lilly and had a return on equity of 61.42% and a net margin of 20.54%. The company’s revenue was down 10.9% compared to the same quarter last year. During the same period last year, the company earned $2.62 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 8.78 EPS for the current year.

Eli Lilly and Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 9th. Stockholders of record on Monday, May 15th will be issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 1.02%. The ex-dividend date is Friday, May 12th. Eli Lilly and’s payout ratio is presently 71.86%.

Insider Activity

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 225,000 shares of the firm’s stock in a transaction on Friday, April 28th. The stock was sold at an average price of $398.48, for a total transaction of $89,658,000.00. Following the completion of the sale, the insider now owns 101,908,810 shares of the company’s stock, valued at approximately $40,608,622,608.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 225,000 shares of the firm’s stock in a transaction on Friday, April 28th. The stock was sold at an average price of $398.48, for a total transaction of $89,658,000.00. Following the completion of the sale, the insider now owns 101,908,810 shares of the company’s stock, valued at approximately $40,608,622,608.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $435.29, for a total value of $261,174.00. Following the sale, the chief accounting officer now directly owns 5,978 shares of the company’s stock, valued at approximately $2,602,163.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,109,251 shares of company stock valued at $411,295,505. 0.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LLY. Silicon Valley Capital Partners bought a new position in shares of Eli Lilly and in the first quarter worth $25,000. Y.D. More Investments Ltd bought a new position in shares of Eli Lilly and in the fourth quarter worth $26,000. Bogart Wealth LLC increased its position in shares of Eli Lilly and by 193.3% in the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after purchasing an additional 58 shares during the period. Destiny Wealth Partners LLC boosted its stake in Eli Lilly and by 97.8% in the fourth quarter. Destiny Wealth Partners LLC now owns 91 shares of the company’s stock valued at $33,000 after buying an additional 45 shares in the last quarter. Finally, Laffer Tengler Investments acquired a new stake in Eli Lilly and in the first quarter valued at about $33,000. Institutional investors own 82.13% of the company’s stock.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.